On the stock market since 1992, it operates in the world of health and science. It has 47 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
No real growth (3% a year). Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
The net profit margin is 46% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 11% a year on average.
There is $733.5M in the vault; even if every debt were paid off, $282.0M would remain.
The company’s market value is 47 times its annual profit. Even a small disappointment could hit the price hard.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, LGND sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: LGND is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.